ACADIA PHARMACEUTICALS INC (ACAD): what the price assumes

In the published model solve dated 2026-Q2, anchored at $28.02, ACADIA PHARMACEUTICALS INC (ACAD) is priced for today's economics sustained for ~11.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/ACAD

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.8% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by asset-based and relative-multiple value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Relative Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=16)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• The single most valuable asset here is a date. A 2023 settlement allows Zydus to launch its generic pimavanserin 10 mg tablet products on September 23, 2036 and 34 mg capsule products on February 27, 2038, subject to certain triggers for earlier launch, which gives the larger of the company's two drugs an unusually long protected life.

• Concentration is the exposure. Two products carry everything, and the most advanced attempt at a third missed: in the Prader-Willi study, ACP-101 did not demonstrate a statistically significant improvement over placebo.

• The next binary event is close. Topline Phase 2 results for remlifanserin in Alzheimer's disease psychosis, an indication with no approved therapy, are expected in September or October 2026, and the FDA granted the programme Fast Track designation on July 20, 2026.

Bull Case

Pharmaceutical companies are usually valued on a countdown. The number that matters most is the year the patents stop working, and for the drug that generates nearly two-thirds of this company's revenue that year is a long way out. Under a settlement reached in 2023, the agreement allows Zydus to launch its generic pimavanserin 10 mg tablet products on September 23, 2036 and 34 mg capsule products on February 27, 2038, subject to certain triggers for earlier launch. Change that date and the whole thesis changes with it. Leave it where it is and Acadia owns more than a decade of protected sales on a product that is still growing: Net product sales of NUPLAZID were $680.1 million and $609.4 million in 2025 and 2024, respectively.

The second product is rarer than the first. DAYBUE is the first and only drug approved for the treatment of Rett syndrome, a severe neurodevelopmental disorder with a small, identifiable and highly motivated patient population. In markets like that, the commercial problem is finding patients rather than beating competitors, and the finding is done once. Across both drugs, Net product sales, comprised of our products, were $1,071.5 million and $957.8 million for the years ended December 31, 2025 and 2024, respectively, which is nearly 12% growth from a base that most specialty pharmaceutical companies would take a decade to build.

Then there is the option that nobody currently owns. Alzheimer's disease psychosis has no approved treatment anywhere, and Acadia is the company that has already proved the underlying mechanism works in a different dementia: NUPLAZID is approved for hallucinations and delusions in Parkinson's disease. Remlifanserin carries the same receptor target into the larger indication, the FDA granted it Fast Track designation on July 20, 2026, and Phase 3 screening is already running in parallel with the Phase 2 readout. Running the confirmatory studies before the earlier data arrives costs money and buys time, which is a rational trade when the indication has no incumbent.

The balance sheet lets the company make that trade without asking anyone's permission. Acadia carries no funded borrowings, the business generates cash rather than consuming it, and the reported operating margin of 7.8% is low precisely because the spending that would otherwise be profit is going into the clinic. That is a choice, not a symptom. A commercial franchise producing over a billion dollars of sales is funding a pipeline that a company without that franchise would have to finance by issuing stock into a falling market.

The peer set shows what the destination looks like when the spending stops. Harmony Biosciences (HRMY), at $899 million of trailing revenue growing 20.7%, runs a 21.1% operating margin. Neurocrine Biosciences (NBIX), at $3.10 billion growing 28.6%, runs 25.4%. Both are neurology specialists with concentrated product lines, and both reached those margins after their pipelines matured rather than during. Acadia's revenue base already sits between them. What it does not yet have is a reason to stop investing, and the September readout is the event that decides whether it gets one.

Bear Case

The structural truth a holder would rather not confront is that last year's profit was mostly an accounting entry. The 10-K is explicit: Prior to fiscal year 2025, we maintained a full valuation allowance against our net deferred tax assets (DTAs) due to a history of cumulative losses, and during 2025 the company concluded it is more likely than not that deferred taxes of $249.9 million are realizable. We therefore reduced the valuation allowance accordingly. Reported net income for the trailing year was $375.7 million, of which roughly two-thirds arrived through that single accounting adjustment. What the business actually earned from selling drugs was operating profit of $82.8 million on more than a billion dollars of sales, a 7.8% operating margin.

That distinction matters more than usual here, because the valuation approaches that appear to support the price are the ones fed by the flattered figures. Book value per share and trailing return on equity both carry the tax entry inside them, and both are inputs to the frames that land closest to the current quote. Strip the entry out and the picture is a specialty pharmaceutical company converting a small single-digit share of revenue into operating profit, which is what the earnings-power approach sees: the price sits about 104% above where those methods land.

The pipeline evidence has been going the wrong way. In September 2025 the company reported that ACP-101 did not demonstrate a statistically significant improvement over placebo in the Prader-Willi study, and in a separate programme Pimavanserin did not demonstrate a statistically significant improvement over placebo in the negative symptoms of schizophrenia. Two shots at broadening beyond the current two products, two misses. The remaining candidate carries the entire expansion case, and its Phase 2 result is a single readout in a single quarter.

Pricing pressure is arriving at the base business at the same time. The filing records an adjustment covering sales from October 1, 2022 to December 31, 2025, which increased our gross-to-net adjustments and reduced our net product sales of NUPLAZID, and separately unfavorable gross-to-net adjustments of approximately $11.8 million related to Medicare inflation cap rebates. Neither is fatal. Both are the beginning of the pattern every US specialty pharmaceutical company now faces, where the gap between list price and realised price widens every year, and it lands on a product whose protected life is long enough for that widening to compound.

Meanwhile the owners are being diluted. The share count has grown about 1.7% a year over the four years to March 2026, and stock-based compensation consumes roughly half of the free cash the business generates. A company whose reported earnings are inflated by a tax entry and whose share count rises every year is putting two separate headwinds between operating performance and per-share results.

Set all of that against what the price demands. The market pays about 44 times what the company earns at the operating line, which requires operating profit to keep growing at its self-funding limit for something like 10 years. Only about 14% of comparable fast-growing companies ever sustained that. The multiple sits at the very top of its peer distribution, well past the upper quartile, and it sits there on a two-product franchise whose expansion depends on a readout that has not happened yet. There is no leverage to fail here and no financing to renegotiate. The risk is simpler than that: pay for a decade of compounding, then find out in October whether the third product exists.

Valuation

At today's price of $24.84, the enterprise is valued at about 44 times what the company earns at the operating line. Inverted, that says operating profit has to keep growing at the fastest rate the business can fund from its own cash flow for something like 10 years. Only about 14% of comparable fast-growing companies ever sustained a run of that length. Against its own sector the multiple sits at the very top of the peer distribution, well past the upper quartile, so this is not a stock the market has overlooked.

A second reading of the same price points the other way and deserves equal airtime. Carried over a shorter horizon the price is consistent with the company sustaining an operating margin of about 4.7%, against the 7.8% it earns now. That version of the requirement is easy. Which of the two readings binds depends entirely on whether you think this is a company that must keep compounding for a decade or one that simply has to hold what it has, and that question is what the September readout answers.

The disagreement among methods is unusual and worth reading carefully. Two families sit above the current quote: the price is about 13% below where book-value-plus-profitability approaches land, and about 15% below where peer multiples land. The forward cash-flow methods sit under it, with the price about 47% above them, and the earnings-power methods sit far under, with the price about 104% above. Ordinarily that configuration would read as a value situation. Here the reading needs a qualification, because the two supportive families take their inputs from a book value and a trailing return on equity of 30.1% that were both lifted by a one-off deferred-tax adjustment during 2025. The frames measuring cash generation rather than accounting equity are the ones landing furthest below the price. That conflict is the analytical question this stock poses; it is not resolvable from the arithmetic alone.

The peer group frames the operating gap plainly. Harmony Biosciences (HRMY) turns $899 million of revenue into a 21.1% operating margin while growing 20.7%. Neurocrine Biosciences (NBIX) manages 25.4% on $3.10 billion, growing 28.6%. Corcept (CORT) and Supernus (SUPN), both closer to Acadia in size, sit at or below breakeven on operating margin, which is the other side of the same trade. Acadia's 7.8% places it between the two groups: too profitable to be a development-stage business, not profitable enough to be valued as a mature franchise.

Solvency is not the constraint and does not need to be forced into the argument. Acadia carries no funded borrowings, the business generates cash rather than absorbing it, and there is no financing event on the horizon that a bad readout would trigger. The dilution runs the other way, with the share count growing about 1.7% a year over the four years to March 2026. What the balance sheet buys is the ability to wait, and waiting is precisely what this valuation is asking a shareholder to do.

Catalysts

One event dominates the next two quarters. Enrollment in the Phase 2 portion of the remlifanserin programme in Alzheimer's disease psychosis is complete, and Acadia expects topline results in September or October 2026. The FDA granted the programme Fast Track designation on July 20, 2026, and the two confirmatory Phase 3 studies are already screening and enrolling in parallel rather than waiting for the earlier data. The indication has no approved therapy of any kind, which is why the readout is binary rather than incremental: the primary endpoint is a six-week change in a hallucinations and delusions score, and the result will either open a market or close a thesis.

The commercial base has been steady while that plays out. First-quarter 2026 revenue reached $268 million, up 10% on the prior year, with NUPLAZID net product sales of $167 million and DAYBUE at $101 million, the latter up 20% and helped by the launch of a new formulation. Management reaffirmed full-year 2026 guidance for total revenue of $1.22 billion to $1.28 billion, comprising $760 million to $790 million from NUPLAZID and $460 million to $490 million from DAYBUE. Those ranges imply the base business grows through the year without needing anything new to arrive.

The company has also put a figure on what it thinks the pipeline candidate is worth, describing peak sales potential for remlifanserin of roughly $4 billion across Alzheimer's disease psychosis and Lewy Body Dementia psychosis. That is management's own estimate of a market that does not exist yet, and it should be read as an ambition rather than a forecast. What makes it worth noting is the scale relative to the existing business: the number is roughly four times current annual revenue, which explains why a single Phase 2 result carries as much weight in this stock as a year of commercial execution.

Peer Cohorts (Per Segment, With Filing Citations)

Development and commercialization of medicines (single segment) (reported)

• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …adversely affect our business, results of operations and future growth prospects, and could cause the market price of our common stock to decline. Only a small number of research and development programs ultimately result in commercially successful drugs. Potential products that appear to be promising at early stages…
• FY2025 10-K: …in clinical development by other companies targeting CAH. • Our investigational treatments for potential use in schizophrenia and depression may in the future compete with several development-stage programs being pursued by other companies. In addition, there are a number of different anti-psychotic, including the…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: …from their commercialization. Moreover, many competitors have substantially greater: • Capital resources; • Research and development resources and experience, including personnel and technology; • Drug development, clinical trial and regulatory resources and experience, including personnel and technology; • Sales and…
• FY2025 10-K: , materially, and permanently impact our revenues, profitability, and cash flows from those products and may substantially limit our ability to obtain a return on the investments we have made in our products. If our competitors develop or market alternatives for the treatment of our target indications, our commercial…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: Because a number of companies compete with us, many of which have greater resources than we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share. Competition from other biotechnology and pharmaceutical…
• FY2025 10-K: …territories where we may seek and obtain regulatory approval, the number of competitors in such markets, the acceptance of the price of WAKIX in those markets and the ability to obtain reimbursement at any price. If the number of our addressable patients is not as large as we estimate or the reasonably accepted…
• CORT (CORCEPT THERAPEUTICS INC)
• FY2025 10-K: The increase of cost of sales as a percentage of revenue for the year ended December 31, 2025 compared to 2024 was primarily due to a decrease in the average selling price of our Products. Research and development expense - Research and development expense includes the cost of (1) recruiting and compensating…
• FY2025 10-K: …industry and the geographical areas from which we recruit. We depend on the principal members of our management and scientific staff. Any officer or employee may terminate his or her relationship with us at any time and work for a competitor. We do not have employment insurance covering any of our personnel. The loss…
• INDV (Indivior Pharmaceuticals, Inc.)
• FY2025 10-K: …on the market in the EU. There are various application procedures available depending on the type of product involved. The centralized procedure gives rise to marketing authorizations that are valid throughout the EU and, by extension (after national implementing decisions), in Norway, Iceland and Liechtenstein,…
• FY2025 10-K: …and processes for the manufacture of products, and intermediate compounds useful in the manufacture of products. Protection for aspects of individual products extends for varying periods in accordance with the expiry dates of patents in the various countries. The protection afforded, which may also vary from country…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …of additional subjects. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates depend on our ability to: • create market demand for…
• FY2025 10-K: …and development experience provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Several of these…
• ALKS (Alkermes plc.)
• FY2025 10-K: …in the commercialization and continued development of products from which we receive revenue and, if our licensees are not effective, or if disputes arise in respect of our contractual arrangements, our revenues could be materially adversely affected; • clinical trials for our product candidates are expensive, may…
• FY2025 10-K: …submissions, which could have a material adverse effect on our business. We may not be able to successfully expand our R&D pipeline or our commercial product portfolio, which could limit our growth potential. Our business is focused on the development and commercialization of medicines in the field of neuroscience,…
• JAZZ (Jazz Pharmaceuticals plc)
• FY2025 10-K: …some EU member states is for reimbursement price of medicinal products to be assessed against the relative price and cost of treatment of existing standard of care and competitor products, which may hinder the inclusion of newer innovative products in reimbursement lists. In December 2025, the European Parliament and…
• FY2025 10-K: …developed at Kent Science Park. As a result, our ability to develop and supply products in a timely and competitive manner depends primarily on third party suppliers being able to meet our ongoing commercial and clinical trial needs for API, other raw materials, packaging materials and finished products. In part due…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.